RESUMEN
BACKGROUND: Typhoid and paratyphoid (enteric fever) are febrile bacterial illnesses common in many low- and middle-income countries. The World Health Organization (WHO) currently recommends treatment with azithromycin, ciprofloxacin, or ceftriaxone due to widespread resistance to older, first-line antimicrobials. Resistance patterns vary in different locations and are changing over time. Fluoroquinolone resistance in South Asia often precludes the use of ciprofloxacin. Extensively drug-resistant strains of enteric fever have emerged in Pakistan. In some areas of the world, susceptibility to old first-line antimicrobials, such as chloramphenicol, has re-appeared. A Cochrane Review of the use of fluoroquinolones and azithromycin in the treatment of enteric fever has previously been undertaken, but the use of cephalosporins has not been systematically investigated and the optimal choice of drug and duration of treatment are uncertain. OBJECTIVES: To evaluate the effectiveness of cephalosporins for treating enteric fever in children and adults compared to other antimicrobials. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, the WHO ICTRP and ClinicalTrials.gov up to 24 November 2021. We also searched reference lists of included trials, contacted researchers working in the field, and contacted relevant organizations. SELECTION CRITERIA: We included randomized controlled trials (RCTs) in adults and children with enteric fever that compared a cephalosporin to another antimicrobial, a different cephalosporin, or a different treatment duration of the intervention cephalosporin. Enteric fever was diagnosed on the basis of blood culture, bone marrow culture, or molecular tests. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were clinical failure, microbiological failure and relapse. Our secondary outcomes were time to defervescence, duration of hospital admission, convalescent faecal carriage, and adverse effects. We used the GRADE approach to assess certainty of evidence for each outcome. MAIN RESULTS: We included 27 RCTs with 2231 total participants published between 1986 and 2016 across Africa, Asia, Europe, the Middle East and the Caribbean, with comparisons between cephalosporins and other antimicrobials used for the treatment of enteric fever in children and adults. The main comparisons are between antimicrobials in most common clinical use, namely cephalosporins compared to a fluoroquinolone and cephalosporins compared to azithromycin. Cephalosporin (cefixime) versus fluoroquinolones Clinical failure, microbiological failure and relapse may be increased in patients treated with cefixime compared to fluoroquinolones in three small trials published over 14 years ago: clinical failure (risk ratio (RR) 13.39, 95% confidence interval (CI) 3.24 to 55.39; 2 trials, 240 participants; low-certainty evidence); microbiological failure (RR 4.07, 95% CI 0.46 to 36.41; 2 trials, 240 participants; low-certainty evidence); relapse (RR 4.45, 95% CI 1.11 to 17.84; 2 trials, 220 participants; low-certainty evidence). Time to defervescence in participants treated with cefixime may be longer compared to participants treated with fluoroquinolones (mean difference (MD) 1.74 days, 95% CI 0.50 to 2.98, 3 trials, 425 participants; low-certainty evidence). Cephalosporin (ceftriaxone) versus azithromycin Ceftriaxone may result in a decrease in clinical failure compared to azithromycin, and it is unclear whether ceftriaxone has an effect on microbiological failure compared to azithromycin in two small trials published over 18 years ago and in one more recent trial, all conducted in participants under 18 years of age: clinical failure (RR 0.42, 95% CI 0.11 to 1.57; 3 trials, 196 participants; low-certainty evidence); microbiological failure (RR 1.95, 95% CI 0.36 to 10.64, 3 trials, 196 participants; very low-certainty evidence). It is unclear whether ceftriaxone increases or decreases relapse compared to azithromycin (RR 10.05, 95% CI 1.93 to 52.38; 3 trials, 185 participants; very low-certainty evidence). Time to defervescence in participants treated with ceftriaxone may be shorter compared to participants treated with azithromycin (mean difference of -0.52 days, 95% CI -0.91 to -0.12; 3 trials, 196 participants; low-certainty evidence). Cephalosporin (ceftriaxone) versus fluoroquinolones It is unclear whether ceftriaxone has an effect on clinical failure, microbiological failure, relapse, and time to defervescence compared to fluoroquinolones in three trials published over 28 years ago and two more recent trials: clinical failure (RR 3.77, 95% CI 0.72 to 19.81; 4 trials, 359 participants; very low-certainty evidence); microbiological failure (RR 1.65, 95% CI 0.40 to 6.83; 3 trials, 316 participants; very low-certainty evidence); relapse (RR 0.95, 95% CI 0.31 to 2.92; 3 trials, 297 participants; very low-certainty evidence) and time to defervescence (MD 2.73 days, 95% CI -0.37 to 5.84; 3 trials, 285 participants; very low-certainty evidence). It is unclear whether ceftriaxone decreases convalescent faecal carriage compared to the fluoroquinolone gatifloxacin (RR 0.18, 95% CI 0.01 to 3.72; 1 trial, 73 participants; very low-certainty evidence) and length of hospital stay may be longer in participants treated with ceftriaxone compared to participants treated with the fluoroquinolone ofloxacin (mean of 12 days (range 7 to 23 days) in the ceftriaxone group compared to a mean of 9 days (range 6 to 13 days) in the ofloxacin group; 1 trial, 47 participants; low-certainty evidence). AUTHORS' CONCLUSIONS: Based on very low- to low-certainty evidence, ceftriaxone is an effective treatment for adults and children with enteric fever, with few adverse effects. Trials suggest that there may be no difference in the performance of ceftriaxone compared with azithromycin, fluoroquinolones, or chloramphenicol. Cefixime can also be used for treatment of enteric fever but may not perform as well as fluoroquinolones. We are unable to draw firm general conclusions on comparative contemporary effectiveness given that most trials were small and conducted over 20 years previously. Clinicians need to take into account current, local resistance patterns in addition to route of administration when choosing an antimicrobial.
Asunto(s)
Antiinfecciosos , Fiebre Paratifoidea , Fiebre Tifoidea , Niño , Adulto , Humanos , Adolescente , Fiebre Paratifoidea/tratamiento farmacológico , Fiebre Tifoidea/tratamiento farmacológico , Cefalosporinas/uso terapéutico , Azitromicina/efectos adversos , Ceftriaxona/uso terapéutico , Cefixima/uso terapéutico , Fluoroquinolonas/uso terapéutico , Antibacterianos/uso terapéutico , Cloranfenicol/uso terapéutico , Antiinfecciosos/uso terapéutico , Monobactamas/uso terapéutico , Ciprofloxacina/uso terapéutico , Ofloxacino/uso terapéutico , Recurrencia , PakistánRESUMEN
This annex study to a phase 1 study aimed to correlate urinary concentrations and bactericidal titers (UBTs) of BAL30072, a novel siderophore monosulfactam, in healthy subjects in order to evaluate which dosage of BAL30072 should be investigated in a clinical study on complicated urinary tract infection (UTI). Three cohorts of a total of 19 healthy male subjects were included in the add-on study and received the following BAL30072 dosages. The 1st cohort received 1 g once a day (q.d.) intravenously (i.v.) (1 h) on day 1 and 1 g thrice daily (t.i.d.) on day 2, the 2nd cohort received 2 g q.d. i.v. (1 h) on day 1 and 2 g t.i.d. on day 2, and the 3rd cohort received 1 g q.d. i.v. (4-h infusion) on day 8. Urine was collected up to 24 h after drug administration. UBTs were determined for seven Escherichia coli isolates (three wild type [WT], CTX-M-15, TEM-3, TEM-5, NDM-1), two Klebsiella pneumoniae isolates (WT, KPC), one Proteus mirabilis isolate (WT), and two Pseudomonas aeruginosa isolates (WT, VIM-1 plus AmpC). Urine drug concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The median urinary excretions of BAL30072 ranged between 38% and 46% (3 cohorts). The median UBTs after i.v. administration of 1 or 2 g q.d. and after 1 or 2 g t.i.d. showed positive UBTs for 24 h after the lowest dosage (1 g q.d.) for 5 of 7 of the Enterobacteriaceae strains and after the higher dosage of 2 g administered i.v. t.i.d. for all strains tested. After i.v. infusion of 1 g over 4 h, positive UBTs were demonstrated for three E. coli strains for up to 12 h, for the K. pneumoniae (KPC) strain for up to 8 h, and for the P. aeruginosa (VIM-1 plus AmpC) strain for up to only 4 h. The minimal bactericidal concentrations (MBCs) of the E. coli (NDM-1) strain and the K. pneumoniae (WT) strain correlated well between broth and urine but did not correlate well for the two P. aeruginosa strains. BAL30072 exhibits positive UBTs for 24 h even after a dosage of 1 g administered i.v. q.d. for 5 of 7 Enterobacteriaceae strains and after 2 g administered i.v. t.i.d. for all strains except one P. aeruginosa strain (50% of the time). In general, the UBTs correlated well with the MICs of the Enterobacteriaceae but were lower for P. aeruginosa The clinical efficacy with a dosage regimen of BAL30072 of 2 g administered i.v. t.i.d. should be evaluated in the treatment of complicated UTI.
Asunto(s)
Antibacterianos/uso terapéutico , Antibacterianos/orina , Monobactamas/uso terapéutico , Monobactamas/orina , Tiazoles/uso terapéutico , Tiazoles/orina , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/orina , Administración Intravenosa , Adulto , Antibacterianos/administración & dosificación , Cromatografía Liquida , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/patogenicidad , Escherichia coli/efectos de los fármacos , Escherichia coli/patogenicidad , Voluntarios Sanos , Humanos , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/patogenicidad , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Monobactamas/administración & dosificación , Proteus mirabilis/efectos de los fármacos , Proteus mirabilis/patogenicidad , Espectrometría de Masas en Tándem , Tiazoles/administración & dosificación , Infecciones Urinarias/microbiologíaRESUMEN
Escherichia coli (328 isolates), Klebsiella pneumoniae (296), Klebsiella oxytoca (44), and Proteus mirabilis (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-ß-lactamase (ESBL) phenotypes were evaluated for the presence of ß-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for K. pneumoniae (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112 K. pneumoniae strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried blaCTX-M. SHV genes encoding ESBL activity were detected among 176 isolates. Other ß-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried ≥2 ß-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC50/90, 0.5/2 µg/ml) and tigecycline (MIC50/90, 0.5/1 µg/ml) were the most active agents tested. Overall, meropenem (MIC50, ≤0.06 µg/ml), ceftazidime-avibactam (MIC50, 0.12 to 0.5 µg/ml), and tigecycline (MIC50, 0.12 to 2 µg/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all ß-lactams tested. The diversity and increasing prevalence of ß-lactamase-producing Enterobacteriaceae have been documented, and ceftazidime-avibactam was very active against the vast majority of ß-lactamase-producing strains isolated from U.S. hospitals.
Asunto(s)
Antibacterianos/uso terapéutico , Ceftazidima/análogos & derivados , Variación Genética , Minociclina/análogos & derivados , Monobactamas/uso terapéutico , Resistencia betalactámica/genética , beta-Lactamasas/genética , Ceftazidima/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Enterobacteriaceae/epidemiología , Infecciones por Enterobacteriaceae/microbiología , Escherichia coli/efectos de los fármacos , Escherichia coli/enzimología , Escherichia coli/genética , Expresión Génica , Humanos , Klebsiella oxytoca/efectos de los fármacos , Klebsiella oxytoca/enzimología , Klebsiella oxytoca/genética , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/genética , Pruebas de Sensibilidad Microbiana , Minociclina/uso terapéutico , Plásmidos , Proteus mirabilis/efectos de los fármacos , Proteus mirabilis/enzimología , Proteus mirabilis/genética , Tigeciclina , Estados Unidos/epidemiología , Resistencia betalactámica/efectos de los fármacos , beta-Lactamasas/metabolismoRESUMEN
The spread of resistance among Gram-positive and Gram-negative bacteria represents a growing challenge for the development of new antimicrobials. The pace of antibiotic drug development has slowed during the last decade and, especially for Gram-negatives, clinicians are facing a dramatic shortage in the availability of therapeutic options to face the emergency of the resistance problem throughout the world. In this alarming scenario, although there is a shortage of compounds reaching the market in the near future, antibiotic discovery remains one of the keys to successfully stem and maybe overcome the tide of resistance. Analogs of already known compounds and new agents belonging to completely new classes of antimicrobials are in early stages of development. Novel and promising anti-Gram-negative antimicrobials belong both to old (cephalosporins, carbapenems, ß-lactamase inhibitors, monobactams, aminoglycosides, polymyxin analogues and tetracycline) and completely new antibacterial classes (boron-containing antibacterial protein synthesis inhibitors, bis-indoles, outer membrane synthesis inhibitors, antibiotics targeting novel sites of the 50S ribosomal subunit and antimicrobial peptides). However, all of these compounds are still far from being introduced into clinical practice. Therefore, infection control policies and optimization in the use of already existing molecules are still the most effective approaches to reduce the spread of resistance and preserve the activity of antimicrobials.
Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Bacterias Gramnegativas/efectos de los fármacos , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Aminoglicósidos/administración & dosificación , Aminoglicósidos/uso terapéutico , Antibacterianos/administración & dosificación , Péptidos Catiónicos Antimicrobianos/administración & dosificación , Péptidos Catiónicos Antimicrobianos/uso terapéutico , Carbapenémicos/administración & dosificación , Carbapenémicos/uso terapéutico , Ensayos Clínicos como Asunto , Esquema de Medicación , Descubrimiento de Drogas , Farmacorresistencia Bacteriana Múltiple/fisiología , Bacterias Gramnegativas/patogenicidad , Bacterias Gramnegativas/fisiología , Infecciones por Bacterias Gramnegativas/microbiología , Humanos , Indoles/administración & dosificación , Indoles/uso terapéutico , Control de Infecciones/organización & administración , Pruebas de Sensibilidad Microbiana , Monobactamas/administración & dosificación , Monobactamas/uso terapéutico , Polimixinas/administración & dosificación , Polimixinas/uso terapéutico , Inhibidores de la Síntesis de la Proteína/administración & dosificación , Inhibidores de la Síntesis de la Proteína/uso terapéutico , beta-Lactamasas/administración & dosificación , beta-Lactamasas/uso terapéuticoRESUMEN
Metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa) is a cause of life-threatening infections. With parenteral colistin not available in Japan, we treated MDR P. aeruginosa sepsis with monobactam and aminoglycoside combination therapy, with screening using a 'break-point checkerboard plate'.
Asunto(s)
Aminoglicósidos/uso terapéutico , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Monobactamas/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , beta-Lactamasas/biosíntesis , Quimioterapia Combinada/métodos , Femenino , Humanos , Japón , Masculino , Pruebas de Sensibilidad Microbiana/métodos , Persona de Mediana Edad , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/aislamiento & purificación , Sepsis/tratamiento farmacológico , Sepsis/microbiología , Resultado del TratamientoRESUMEN
BACKGROUND: beta-lactams are our most valuable and frequently used antibiotics. Resistance towards them, in both Gram-positive and Gram-negative bacteria, challenges their antimicrobial effect. beta-lactamases are the most important resistance mechanism against beta-lactams in Gram-negative bacteria. MATERIAL AND METHODS: This review is based on literature retrieved through a non-systematic search of Pubmed (with the terms "ESBL", "AmpC", and "carbapenemases"), as well as the authors' own research experience. RESULTS AND INTERPRETATION: We now observe a global dissemination of particularly broad spectrum beta-lactamases; extended-spectrum beta-lactamases (ESBLs), plasmid-mediated AmpC, and carbapenemases. These beta-lactamases are hosted by multidrug-resistant clones of Enterobacteriaceae, Pseudomonas aeruginosa with few, if any, therapeutic alternatives. We have observed that this pandemic has reached Norway with an increase in ESBL-producing Escherichia coli in particular, but also pan-resistant carbapenemase-producing K. pneumoniae, P. aeruginosa OG A. baumannii during the last years. The latter ones have been associated with import after hospitalization abroad, but this situation may change due to the epidemic potential of these resistant clones. Rapid diagnostic service and targeted infection control measures are important to prevent them from spreading.
Asunto(s)
Antibacterianos/uso terapéutico , Bacterias Gramnegativas/enzimología , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Resistencia betalactámica , beta-Lactamasas/metabolismo , beta-Lactamas/uso terapéutico , Proteínas Bacterianas/biosíntesis , Proteínas Bacterianas/metabolismo , Carbapenémicos/uso terapéutico , Cefalosporinas/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Humanos , Pruebas de Sensibilidad Microbiana , Monobactamas/uso terapéutico , Penicilinas/uso terapéutico , Plásmidos , Resistencia betalactámica/efectos de los fármacos , beta-Lactamasas/biosíntesisRESUMEN
We have previously reported that the Neisseria gonorrhoeae isolates from clinical failure cases treated with cefdinir and aztreonam, beta-lactams exhibited high MICs. These resistant isolates were clearly separated from the isolates exhibiting a low level of resistance to beta-lactams as shown by the MIC distribution of cefozopran. Restriction fragment length polymorphism DNA typing revealed that the outbreak of cefozopran-resistant isolates in Kitakyushu, Japan, occurred as a result of clonal spread.
Asunto(s)
Antibacterianos/uso terapéutico , Cefalosporinas/uso terapéutico , Gonorrea/tratamiento farmacológico , Neisseria gonorrhoeae/efectos de los fármacos , Adulto , Aztreonam/farmacología , Aztreonam/uso terapéutico , Cefalosporinas/farmacología , ADN Bacteriano/genética , Brotes de Enfermedades , Farmacorresistencia Microbiana , Resistencia a Múltiples Medicamentos , Femenino , Gonorrea/epidemiología , Gonorrea/microbiología , Humanos , Japón/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Monobactamas/uso terapéutico , Neisseria gonorrhoeae/genética , Penicilinas/farmacología , Penicilinas/uso terapéutico , Polimorfismo de Longitud del Fragmento de Restricción , CefozopránRESUMEN
BACKGROUND: Urinary tract infection is a very common problem in adults as well as in children. There is always need for the right antibiotic to be chosen for treatment. METHODS: This study was conducted at Microbiology section in Pathology department of Ayub Medical College, Abbottabad, Pakistan. In this study the aztronam which is only effective against gram negative bacilli has been compared with other conventionally used antibiotics, ampicillin, cotrimoxazole, minocyclin, pipemedic acid, nalidixic acid, norfloxacin, ciprofloxacin, gentamicin and ceftriaxon. RESULTS: Total gram negative isolates were 342. Out of this 76.6% (262) were E. coli, klebsiella pneumoniae 14.3% (49), proteus species 5.2%(18) and pseudomonas aeruginosa were 3.8% (13). The aztreonam showed 78% sensitivity against gram negative bacilli which is better than norfloxacin which showed 62.2% sensitivity.
Asunto(s)
Antiinfecciosos Urinarios/uso terapéutico , Aztreonam/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico , Humanos , Pruebas de Sensibilidad Microbiana , Monobactamas/uso terapéuticoRESUMEN
The effect of antibiotics on the acute lung injury induced by virulent Pseudomonas aeruginosa PA103 was quantitatively analyzed in a rat model. Lung injury was induced by the instillation of PA103 directly into the right lower lobes of the lungs of anesthetized rats. The alveolar epithelial injury, extravascular lung water, and total plasma equivalents were measured as separate, independent parameters of acute lung injury. Four hours after the instillation of PA103, all the parameters were increased linearly depending on the dose of P. aeruginosa. Next, we examined the effects of intravenously administered antibiotics on the parameters of acute lung injury in D-galactosamine-sensitized rats. One hour after the rats received 10(7) CFU of PA103, an intravenous bolus injection of aztreonam (60 mg/kg) or imipenem-cilastatin (30 mg/kg) was administered. Despite an MIC indicating resistance, imipenem-cilastatin improved all the measurements of lung injury; in contrast, aztreonam, which had an MIC indicating sensitivity, did not improve any of the lung injury parameters. The antibiotics did not generate different quantities of plasma endotoxin; therefore, endotoxin did not appear to explain the differences in lung injury. This in vivo model is useful to quantitatively compare the efficacies of parenteral antibiotic administration on Pseudomonas airspace infections.
Asunto(s)
Quimioterapia Combinada/uso terapéutico , Enfermedades Pulmonares/patología , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Animales , Aztreonam/farmacología , Aztreonam/uso terapéutico , Cilastatina/farmacología , Cilastatina/uso terapéutico , Combinación Cilastatina e Imipenem , Modelos Animales de Enfermedad , Combinación de Medicamentos , Quimioterapia Combinada/farmacología , Imipenem/farmacología , Imipenem/uso terapéutico , Enfermedades Pulmonares/microbiología , Masculino , Pruebas de Sensibilidad Microbiana , Monobactamas/farmacología , Monobactamas/uso terapéutico , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/patogenicidad , Ratas , Ratas Sprague-DawleyRESUMEN
The differential tissue distributions of aztreonam and ceftazidime within fibrin clots infected with Pseudomonas aeruginosa, Enterobacter cloacae, and Serratia marcescens, their efficacies, and the in vivo bacterial morphological changes induced by these drugs were evaluated. Rabbits were given intravenously a single dose of 100 mg of either agents/kg of body weight. In the cores of the clots, the peak levels of both drugs were much lower than those observed in the peripheries and in serum. Aztreonam's half-lives within the peripheries and in the cores of the fibrin clots were up to six times higher than observed in serum, while ceftazidime's half-lives in clots were twice that observed in serum. This resulted in a much greater penetration ratio for aztreonam than for ceftazidime. Both drugs controlled the growth of P. aeruginosa in vivo, but E. cloacae and S. marcescens responded better to ceftazidime. Morphological changes were more abundant in the peripheries than in the cores of the clots. In the control group, P. aeruginosa's morphology in the cores was different than that in the peripheries of the clots. Against P. aeruginosa, aztreonam did induce morphological changes in the cores while ceftazidime did not. Electron microscopic studies revealed that morphological changes associated with aztreonam seemed different than those of ceftazidime. Along with elongation of bacteria, more bow tie and herniated bacteria were observed with aztreonam. Though both agents selectively affect PBP 3, as manifested by elongated bacteria, they induce in the peripheries of the clots thickening, breaks, and detachment in bacterial cell walls, alterations which are generally associated with antibiotics affecting PBP 1a and 1b.
Asunto(s)
Aztreonam/farmacología , Ceftazidima/farmacología , Cefalosporinas/farmacología , Enterobacter cloacae/efectos de los fármacos , Monobactamas/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Serratia marcescens/efectos de los fármacos , Animales , Aztreonam/farmacocinética , Aztreonam/uso terapéutico , Ceftazidima/farmacocinética , Ceftazidima/uso terapéutico , Cefalosporinas/farmacocinética , Cefalosporinas/uso terapéutico , Enterobacter cloacae/ultraestructura , Infecciones por Enterobacteriaceae/sangre , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Femenino , Fibrina , Pruebas de Sensibilidad Microbiana , Monobactamas/farmacocinética , Monobactamas/uso terapéutico , Infecciones por Pseudomonas/sangre , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/ultraestructura , Conejos , Infecciones por Serratia/sangre , Infecciones por Serratia/tratamiento farmacológico , Serratia marcescens/ultraestructuraRESUMEN
The efficacy of the prophylactic use of azthreonam, a monocyclic beta lactam antibiotic, was studied in 20 patients operated for liver diseases. The drug was administered intramuscularly in a dose of 1 g 30 minutes prior to the operation. During the postoperative period the drug was administered in a dose of 1 g 4-5 times a day for 4 to 5 days. The clinical effect in all the patients was good: no elevation of the body temperature above 37.5 degrees C and no suppuration of the operation wound. Adverse reaction to the treatment were not observed. 135 clinical isolates were tested for the susceptibility to azthreonam. The most susceptible gram-negative bacteria were the following: E coli (100 per cent), P. mirabilis (100 per cent), M. morganii (100 per cent), P. rettgeri (100 per cent) and Citrobacter sp. (84 per cent). P. aeruginosa, Acinetobacter, P. vulgaris and Enterobacter were less susceptible (64, 50, 50 and 47.5 per cent respectively). All the S. aureus isolates were resistant.
Asunto(s)
Aztreonam/uso terapéutico , Hepatopatías/cirugía , Monobactamas/uso terapéutico , Infección de la Herida Quirúrgica/prevención & control , Bacterias Gramnegativas/efectos de los fármacos , Humanos , Pruebas de Sensibilidad MicrobianaRESUMEN
Dealing with infections is an integral part of clinical practice. The vast number of antimicrobial agents available, with new ones being introduced constantly, behooves practitioners to keep abreast of the properties, antimicrobial activities, clinical uses and possible adverse effects of these agents. This article attempts to present an overview on several classes of antimicrobial agents commonly used in our daily practices, with the hope of steering our colleagues toward rational and judicious usage of these potent medications.
Asunto(s)
Antibacterianos/uso terapéutico , 4-Quinolonas , Aminoglicósidos , Antiinfecciosos/uso terapéutico , Carbapenémicos/uso terapéutico , Cefalosporinas/uso terapéutico , Humanos , Macrólidos , Pruebas de Sensibilidad Microbiana , Monobactamas/uso terapéutico , Penicilinas/uso terapéutico , Sulfonamidas/uso terapéutico , Vancomicina/uso terapéuticoAsunto(s)
Antibacterianos/uso terapéutico , Carbapenémicos/uso terapéutico , Enfermedades Urogenitales Femeninas/tratamiento farmacológico , Enfermedades Urogenitales Masculinas , Monobactamas/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico , Inhibidores de beta-Lactamasas , Humanos , Macrólidos , Pruebas de Sensibilidad MicrobianaRESUMEN
Antibiotics have dramatically changed the care of the critically ill patient over the last 60 years. Patients with complex physiological conditions present with infectious processes requiring the effective use of antimicrobial drugs. In many situations, the inability to eradicate the infectious process is complicated by the progressive development of resistance among the causative organisms. Systemic antibiotic prophylaxis is warranted only for the prevention of wound infections. Regimens in these cases should use large doses of nontoxic antibiotics covering the spectrum of organisms likely to contaminate the wound. The duration of wound prophylaxis should be short, essentially covering only the period of active wound closure; this is usually less than 24 hours. Prevention of most other infections in the ICU depends on the recognition and correction of the various disturbances of host defenses. Topical antibiotic therapy may reduce the level of colonization for a few specific types of infection. Initial empiric antibiotic therapy should be started for clear indications. The antibiotics chosen should be those most likely to be effective against the probable organisms, those which have the lowest toxicity, and those with the smallest likelihood of inducing multiresistance. They must be adjusted promptly based on the microbiologic sensitivities observed. The realization that the physiology of critical illness may alter the normal relations between drug dosages and the tissue antibiotic levels obtained mandates a different approach to the treatment of these patients. The drug volumes of distribution are generally markedly expanded in these patients. Furthermore, these patients require high tissue antibiotic concentrations to improve the chances for successful therapy. Thus, the antibiotics selected must be capable of providing these levels without significant toxicity to the host. Therapy should be continued based on the clinical response observed. Premature cessation of effective therapy often results in relapse.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/prevención & control , Cuidados Críticos/métodos , Infección de la Herida Quirúrgica/prevención & control , Aminoglicósidos/uso terapéutico , Antibacterianos/administración & dosificación , Antifúngicos/uso terapéutico , Carbapenémicos/uso terapéutico , Cefalosporinas/uso terapéutico , Farmacorresistencia Microbiana , Humanos , Unidades de Cuidados Intensivos , Pruebas de Sensibilidad Microbiana , Monobactamas/uso terapéutico , Micosis/tratamiento farmacológico , Micosis/prevención & control , Penicilinas/uso terapéutico , Neumonía/prevención & control , Vancomicina/uso terapéuticoRESUMEN
A study was performed to investigate the pharmacodynamics of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo. The in vitro concentration-effect relationships were determined in short-term growth experiments. The in vivo dose-effect relationships were determined in an experimental thigh muscle infection in irradiated mice. In this model, E. coli was injected into one thigh muscle and K. pneumoniae was injected into the other. Throughout these experiments aztreonam was administered subcutaneously and tigemonam was administered orally. For analysis of the antibacterial pharmacodynamics, the following parameters were determined: the maximum effect as a parameter for efficacy, the 50% effective concentration (or dose) as a parameter for potency, and the slope of the concentration-effect relationship. To assess the relationship between the concentration of the antibiotic and the antibacterial effect in vivo, the pharmacokinetics of the two drugs in the plasma of mice were determined as well. The maximum in vitro and in vivo effects of aztreonam and tigemonam against both bacteria did not differ substantially. However, both drugs killed E. coli more effectively than K. pneumoniae, indicating that the maximum in vitro effect of these drugs against E. coli was higher than that against K. pneumoniae. The maximum in vivo effect of both drugs against E. coli was similar to that against K. pneumoniae. Furthermore, in vitro aztreonam was about twice as potent as tigemonam, but in vivo the reverse was the case. These findings were explained by pharmacokinetic differences between subcutaneously administered aztreonam and orally administered tigemonam, because concentrations of tigemonam in plasma remained at microbiologically active concentrations longer than those of aztreonam did.